DENDREON CORPORATION (DNDNQ)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

1301 2ND AVE. SEATTLE, WA 98101

Discovers, develops and commercializes targeted therapies for cancer. This biotechnology company's portfolio of product candidates includes active immunotherapies, monoclonal antibodies and small molecules to treat a range of cancers. Its most advanced product candidate is Provenge.

View SEC Filings from DNDNQ instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 1 1 0.0% (0.0%) (0.0%)
13F shares: 0 0
% Ownership
New Positions:
Increased Positions
Closed Positions
Reduced Positions
Total Calls
Total Puts
PUT/CALL Ratio
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding DNDNQ (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding DNDNQ BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BROPHY KAREN VP, HUMAN RESOURCES

  • Officer
No longer subject to file 2015-02-23 0

PACHECO SILVIO SVP, SALES AND MARKETING

  • Officer
No longer subject to file 2015-02-23 0

CROTTY ROBERT EVP, GENERAL COUNSEL

  • Officer
97,855 2015-02-17 0

COX GREG EVP, CFO & TREASURER

  • Officer
177,754 2015-02-13 0

MONTEITH WILLIAM EVP, TECHNICAL OPERATIONS

  • Officer
209,875 2015-02-13 0

SANDLER ANDREW SETH EVP, CHIEF MEDICAL OFFICER

  • Officer
207,914 2015-02-13 0

JENKINSON WILLIAM CHIEF MARKETING OFFICER

  • Officer
98,436 2014-08-31 0

ROCCO LINDSAY EVP, CORPORATE COMMUNICATIONS

  • Officer
122,998 2014-08-15 0

AMICK W THOMAS PRES & CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
125,000 2014-07-31 0

JOHNSON JOHN PRES & CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
1,071,125 2014-07-03 0

CVIJIC CHRISTINE MIKAIL EVP, CORP DEV, GEN CNSL/SCRTRY

  • Officer
351,465 2014-02-10 0

DEPINTO JOSEPH I EVP, GLOBAL COMMERCIAL OPS

  • Officer
136,694 2014-01-31 0

FROHLICH MARK W EVP, R&D AND CMO

  • Officer
525,283 2014-01-20 0

URDAL DAVID

  • Director
644,750 2014-01-03 0

BAYH SUSAN B

  • Director
115,757 2014-01-03 0

FENTON DENNIS M

  • Director
75,000 2014-01-03 0

DZIURZYNSKI BOGDAN

  • Director
103,507 2014-01-03 0

WATSON DOUGLAS G

  • Director
104,757 2014-01-03 0

STUMP DAVID C

  • Director
82,047 2014-01-03 0

GRANADILLO PEDRO P

  • Director
87,251 2014-01-03 0

SCHIFFMAN GREGORY T EVP

  • Officer
441,924 2013-10-20 0

RANIERI RICHARD J EVP, HUMAN RESOURCES

  • Officer
224,831 2013-01-31 0

MAYES, GREGORY T. EVP HUMAN RESOURCES

  • Officer
150,000 2013-01-31 0

GOLD MITCHELL

  • Director
457,263 2013-01-03 0

CANET GERARDO

  • Director
74,757 2013-01-03 0

POULTON ROBERT S EVP, TECHNICAL OPERATIONS

  • Officer
112,957 2013-01-03 0

OSBORN JOHN E EVP, GENERAL COUNSEL

  • Officer
187,000 2012-01-03 0

BREWER RICHARD B

  • Director
45,157 2012-01-03 0

BISHOP HANS EDGAR CHIEF OPERATING OFFICER

  • Officer
151,189 2011-07-29 0

HAMM RICHARD F JR EVP, GENERAL COUNSEL SECRETARY

  • Officer
180,633 2011-05-23 0

CLARK IAN T BOARD OF DIRECTOR

  • Director
0 2010-08-20 0

INGLE M BLAKE

  • Director
12,500 2009-04-29 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments